Product How it works Pricing Blog FAQ About Contact
Cytek Biosciences

Cytek Biosciences (NASDAQ: CTKB) net income

Cytek Biosciences reported a net loss of $66.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $6.0m.

Cytek Biosciences's best year of the last 6 was fiscal 2020. The biggest drop was in fiscal 2021, −84.4%. It reported a loss in 3 of those 6 years.

Net income, in millions of US dollars19.420203.020212.52022-12.12023-6.02024-66.52025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$66.5m—−33.0%—
2024−$6.0m—−3.0%—
2023−$12.1m−589.0%−6.3%−$0.09
2022$2.5m−17.9%1.5%$0.02
2021$3.0m−84.4%2.4%$0.00
2020$19.4m—20.9%$0.11

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Cytek Biosciences net income compared with its sector

By net income for its latest fiscal year, Cytek Biosciences ranks 288th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Cytek Biosciences, −33.0%.

RankCompanyNet incomeNet margin
286thTarsus Pharmaceuticals−$66.4m−14.7%
287thCompass Therapeutics−$66.5m—
288thCytek Biosciences−$66.5m−33.0%
289thOcugen−$67.8m−1,537.4%
290thZura Bio−$68.7m—

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Cytek Biosciences

How much did Cytek Biosciences earn in fiscal 2025?
Cytek Biosciences reported a net loss of $66.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $6.0m.
What was the most profitable year for Cytek Biosciences?
Of its last 6 fiscal years, fiscal 2020, with $19.4m.
Where does Cytek Biosciences rank in its sector by net income?
It ranks 288th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Cytek Biosciences come from?
From the annual report (Form 10-K) that Cytek Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Cytek Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Cytek Biosciences: the Cytek Biosciences page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.